Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

This copy is for your personal, non-commercial use only ... Those who lose weight on Ozempic often find success has left them with sagging skin—a common side effect that is driving a boom ...

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

The current list price for Ozempic is $997.58 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card for those with commercial or private insurance who are ...

Mounjaro and Ozempic have FDA approval for type 2 diabetes treatment, but not specifically for weight loss. So, chances are most commercial insurance plans won’t cover them for weight loss.

Hims & Hers' Super Bowl ad for unapproved weight loss drugs faces backlash from health experts over safety concerns.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...